Search

Your search keyword '"Sudo, Kazuki"' showing total 75 results
Start Over Author "Sudo, Kazuki" Publisher american association for cancer research (aacr)
75 results on '"Sudo, Kazuki"'

1. Supplementary Table S4 from Clinical Activity and Exploratory Resistance Mechanism of Milademetan, an MDM2 Inhibitor, in Intimal Sarcoma with MDM2 Amplification: An Open-Label Phase Ib/II Study

Author

Koyama, Takafumi, primary, Shimizu, Toshio, primary, Kojima, Yuki, primary, Sudo, Kazuki, primary, Okuma, Hitomi Sumiyoshi, primary, Shimoi, Tatsunori, primary, Ichikawa, Hitoshi, primary, Kohsaka, Shinji, primary, Sadachi, Ryo, primary, Hirakawa, Akihiro, primary, Yoshida, Akihiko, primary, Ando, Reiko Makihara, primary, Ueno, Toshihide, primary, Yanagaki, Mitsuru, primary, Matsui, Naoko, primary, Nakamura, Kenichi, primary, Yamamoto, Noboru, primary, and Yonemori, Kan, primary

Published
2023
Full Text
View/download PDF

2. Supplementary Table S1 from Clinical Activity and Exploratory Resistance Mechanism of Milademetan, an MDM2 Inhibitor, in Intimal Sarcoma with MDM2 Amplification: An Open-Label Phase Ib/II Study

Author

Koyama, Takafumi, primary, Shimizu, Toshio, primary, Kojima, Yuki, primary, Sudo, Kazuki, primary, Okuma, Hitomi Sumiyoshi, primary, Shimoi, Tatsunori, primary, Ichikawa, Hitoshi, primary, Kohsaka, Shinji, primary, Sadachi, Ryo, primary, Hirakawa, Akihiro, primary, Yoshida, Akihiko, primary, Ando, Reiko Makihara, primary, Ueno, Toshihide, primary, Yanagaki, Mitsuru, primary, Matsui, Naoko, primary, Nakamura, Kenichi, primary, Yamamoto, Noboru, primary, and Yonemori, Kan, primary

Published
2023
Full Text
View/download PDF

3. Supplementary Figure S2 from Clinical Activity and Exploratory Resistance Mechanism of Milademetan, an MDM2 Inhibitor, in Intimal Sarcoma with MDM2 Amplification: An Open-Label Phase Ib/II Study

Author

Koyama, Takafumi, primary, Shimizu, Toshio, primary, Kojima, Yuki, primary, Sudo, Kazuki, primary, Okuma, Hitomi Sumiyoshi, primary, Shimoi, Tatsunori, primary, Ichikawa, Hitoshi, primary, Kohsaka, Shinji, primary, Sadachi, Ryo, primary, Hirakawa, Akihiro, primary, Yoshida, Akihiko, primary, Ando, Reiko Makihara, primary, Ueno, Toshihide, primary, Yanagaki, Mitsuru, primary, Matsui, Naoko, primary, Nakamura, Kenichi, primary, Yamamoto, Noboru, primary, and Yonemori, Kan, primary

Published
2023
Full Text
View/download PDF

4. Supplementary Table S7 from Clinical Activity and Exploratory Resistance Mechanism of Milademetan, an MDM2 Inhibitor, in Intimal Sarcoma with MDM2 Amplification: An Open-Label Phase Ib/II Study

Author

Koyama, Takafumi, primary, Shimizu, Toshio, primary, Kojima, Yuki, primary, Sudo, Kazuki, primary, Okuma, Hitomi Sumiyoshi, primary, Shimoi, Tatsunori, primary, Ichikawa, Hitoshi, primary, Kohsaka, Shinji, primary, Sadachi, Ryo, primary, Hirakawa, Akihiro, primary, Yoshida, Akihiko, primary, Ando, Reiko Makihara, primary, Ueno, Toshihide, primary, Yanagaki, Mitsuru, primary, Matsui, Naoko, primary, Nakamura, Kenichi, primary, Yamamoto, Noboru, primary, and Yonemori, Kan, primary

Published
2023
Full Text
View/download PDF

5. Supplementary Table S2 from Clinical Activity and Exploratory Resistance Mechanism of Milademetan, an MDM2 Inhibitor, in Intimal Sarcoma with MDM2 Amplification: An Open-Label Phase Ib/II Study

Author

Koyama, Takafumi, primary, Shimizu, Toshio, primary, Kojima, Yuki, primary, Sudo, Kazuki, primary, Okuma, Hitomi Sumiyoshi, primary, Shimoi, Tatsunori, primary, Ichikawa, Hitoshi, primary, Kohsaka, Shinji, primary, Sadachi, Ryo, primary, Hirakawa, Akihiro, primary, Yoshida, Akihiko, primary, Ando, Reiko Makihara, primary, Ueno, Toshihide, primary, Yanagaki, Mitsuru, primary, Matsui, Naoko, primary, Nakamura, Kenichi, primary, Yamamoto, Noboru, primary, and Yonemori, Kan, primary

Published
2023
Full Text
View/download PDF

6. Supplementary Table S8 from Clinical Activity and Exploratory Resistance Mechanism of Milademetan, an MDM2 Inhibitor, in Intimal Sarcoma with MDM2 Amplification: An Open-Label Phase Ib/II Study

Author

Koyama, Takafumi, primary, Shimizu, Toshio, primary, Kojima, Yuki, primary, Sudo, Kazuki, primary, Okuma, Hitomi Sumiyoshi, primary, Shimoi, Tatsunori, primary, Ichikawa, Hitoshi, primary, Kohsaka, Shinji, primary, Sadachi, Ryo, primary, Hirakawa, Akihiro, primary, Yoshida, Akihiko, primary, Ando, Reiko Makihara, primary, Ueno, Toshihide, primary, Yanagaki, Mitsuru, primary, Matsui, Naoko, primary, Nakamura, Kenichi, primary, Yamamoto, Noboru, primary, and Yonemori, Kan, primary

Published
2023
Full Text
View/download PDF

7. Supplementary Figure S1 from Clinical Activity and Exploratory Resistance Mechanism of Milademetan, an MDM2 Inhibitor, in Intimal Sarcoma with MDM2 Amplification: An Open-Label Phase Ib/II Study

Author

Koyama, Takafumi, primary, Shimizu, Toshio, primary, Kojima, Yuki, primary, Sudo, Kazuki, primary, Okuma, Hitomi Sumiyoshi, primary, Shimoi, Tatsunori, primary, Ichikawa, Hitoshi, primary, Kohsaka, Shinji, primary, Sadachi, Ryo, primary, Hirakawa, Akihiro, primary, Yoshida, Akihiko, primary, Ando, Reiko Makihara, primary, Ueno, Toshihide, primary, Yanagaki, Mitsuru, primary, Matsui, Naoko, primary, Nakamura, Kenichi, primary, Yamamoto, Noboru, primary, and Yonemori, Kan, primary

Published
2023
Full Text
View/download PDF

8. Supplementary Table S5B from Clinical Activity and Exploratory Resistance Mechanism of Milademetan, an MDM2 Inhibitor, in Intimal Sarcoma with MDM2 Amplification: An Open-Label Phase Ib/II Study

Author

Koyama, Takafumi, primary, Shimizu, Toshio, primary, Kojima, Yuki, primary, Sudo, Kazuki, primary, Okuma, Hitomi Sumiyoshi, primary, Shimoi, Tatsunori, primary, Ichikawa, Hitoshi, primary, Kohsaka, Shinji, primary, Sadachi, Ryo, primary, Hirakawa, Akihiro, primary, Yoshida, Akihiko, primary, Ando, Reiko Makihara, primary, Ueno, Toshihide, primary, Yanagaki, Mitsuru, primary, Matsui, Naoko, primary, Nakamura, Kenichi, primary, Yamamoto, Noboru, primary, and Yonemori, Kan, primary

Published
2023
Full Text
View/download PDF

9. Supplementary Figure S4B from Clinical Activity and Exploratory Resistance Mechanism of Milademetan, an MDM2 Inhibitor, in Intimal Sarcoma with MDM2 Amplification: An Open-Label Phase Ib/II Study

Author

Koyama, Takafumi, primary, Shimizu, Toshio, primary, Kojima, Yuki, primary, Sudo, Kazuki, primary, Okuma, Hitomi Sumiyoshi, primary, Shimoi, Tatsunori, primary, Ichikawa, Hitoshi, primary, Kohsaka, Shinji, primary, Sadachi, Ryo, primary, Hirakawa, Akihiro, primary, Yoshida, Akihiko, primary, Ando, Reiko Makihara, primary, Ueno, Toshihide, primary, Yanagaki, Mitsuru, primary, Matsui, Naoko, primary, Nakamura, Kenichi, primary, Yamamoto, Noboru, primary, and Yonemori, Kan, primary

Published
2023
Full Text
View/download PDF

10. Supplementary Table S5B from Clinical Activity and Exploratory Resistance Mechanism of Milademetan, an MDM2 Inhibitor, in Intimal Sarcoma with MDM2 Amplification: An Open-Label Phase Ib/II Study

Author

Koyama, Takafumi, primary, Shimizu, Toshio, primary, Kojima, Yuki, primary, Sudo, Kazuki, primary, Okuma, Hitomi Sumiyoshi, primary, Shimoi, Tatsunori, primary, Ichikawa, Hitoshi, primary, Kohsaka, Shinji, primary, Sadachi, Ryo, primary, Hirakawa, Akihiro, primary, Yoshida, Akihiko, primary, Ando, Reiko Makihara, primary, Ueno, Toshihide, primary, Yanagaki, Mitsuru, primary, Matsui, Naoko, primary, Nakamura, Kenichi, primary, Yamamoto, Noboru, primary, and Yonemori, Kan, primary

Published
2023
Full Text
View/download PDF

11. Supplementary Table S3A-B from Clinical Activity and Exploratory Resistance Mechanism of Milademetan, an MDM2 Inhibitor, in Intimal Sarcoma with MDM2 Amplification: An Open-Label Phase Ib/II Study

Author

Koyama, Takafumi, primary, Shimizu, Toshio, primary, Kojima, Yuki, primary, Sudo, Kazuki, primary, Okuma, Hitomi Sumiyoshi, primary, Shimoi, Tatsunori, primary, Ichikawa, Hitoshi, primary, Kohsaka, Shinji, primary, Sadachi, Ryo, primary, Hirakawa, Akihiro, primary, Yoshida, Akihiko, primary, Ando, Reiko Makihara, primary, Ueno, Toshihide, primary, Yanagaki, Mitsuru, primary, Matsui, Naoko, primary, Nakamura, Kenichi, primary, Yamamoto, Noboru, primary, and Yonemori, Kan, primary

Published
2023
Full Text
View/download PDF

12. Supplementary Figure S6 from Clinical Activity and Exploratory Resistance Mechanism of Milademetan, an MDM2 Inhibitor, in Intimal Sarcoma with MDM2 Amplification: An Open-Label Phase Ib/II Study

Author

Koyama, Takafumi, primary, Shimizu, Toshio, primary, Kojima, Yuki, primary, Sudo, Kazuki, primary, Okuma, Hitomi Sumiyoshi, primary, Shimoi, Tatsunori, primary, Ichikawa, Hitoshi, primary, Kohsaka, Shinji, primary, Sadachi, Ryo, primary, Hirakawa, Akihiro, primary, Yoshida, Akihiko, primary, Ando, Reiko Makihara, primary, Ueno, Toshihide, primary, Yanagaki, Mitsuru, primary, Matsui, Naoko, primary, Nakamura, Kenichi, primary, Yamamoto, Noboru, primary, and Yonemori, Kan, primary

Published
2023
Full Text
View/download PDF

13. Supplementary Figure S4B from Clinical Activity and Exploratory Resistance Mechanism of Milademetan, an MDM2 Inhibitor, in Intimal Sarcoma with MDM2 Amplification: An Open-Label Phase Ib/II Study

Author

Koyama, Takafumi, primary, Shimizu, Toshio, primary, Kojima, Yuki, primary, Sudo, Kazuki, primary, Okuma, Hitomi Sumiyoshi, primary, Shimoi, Tatsunori, primary, Ichikawa, Hitoshi, primary, Kohsaka, Shinji, primary, Sadachi, Ryo, primary, Hirakawa, Akihiro, primary, Yoshida, Akihiko, primary, Ando, Reiko Makihara, primary, Ueno, Toshihide, primary, Yanagaki, Mitsuru, primary, Matsui, Naoko, primary, Nakamura, Kenichi, primary, Yamamoto, Noboru, primary, and Yonemori, Kan, primary

Published
2023
Full Text
View/download PDF

14. Supplementary Figure S4A from Clinical Activity and Exploratory Resistance Mechanism of Milademetan, an MDM2 Inhibitor, in Intimal Sarcoma with MDM2 Amplification: An Open-Label Phase Ib/II Study

Author

Koyama, Takafumi, primary, Shimizu, Toshio, primary, Kojima, Yuki, primary, Sudo, Kazuki, primary, Okuma, Hitomi Sumiyoshi, primary, Shimoi, Tatsunori, primary, Ichikawa, Hitoshi, primary, Kohsaka, Shinji, primary, Sadachi, Ryo, primary, Hirakawa, Akihiro, primary, Yoshida, Akihiko, primary, Ando, Reiko Makihara, primary, Ueno, Toshihide, primary, Yanagaki, Mitsuru, primary, Matsui, Naoko, primary, Nakamura, Kenichi, primary, Yamamoto, Noboru, primary, and Yonemori, Kan, primary

Published
2023
Full Text
View/download PDF

15. Supplementary Table S2 from Clinical Activity and Exploratory Resistance Mechanism of Milademetan, an MDM2 Inhibitor, in Intimal Sarcoma with MDM2 Amplification: An Open-Label Phase Ib/II Study

Author

Koyama, Takafumi, primary, Shimizu, Toshio, primary, Kojima, Yuki, primary, Sudo, Kazuki, primary, Okuma, Hitomi Sumiyoshi, primary, Shimoi, Tatsunori, primary, Ichikawa, Hitoshi, primary, Kohsaka, Shinji, primary, Sadachi, Ryo, primary, Hirakawa, Akihiro, primary, Yoshida, Akihiko, primary, Ando, Reiko Makihara, primary, Ueno, Toshihide, primary, Yanagaki, Mitsuru, primary, Matsui, Naoko, primary, Nakamura, Kenichi, primary, Yamamoto, Noboru, primary, and Yonemori, Kan, primary

Published
2023
Full Text
View/download PDF

16. Data from Clinical Activity and Exploratory Resistance Mechanism of Milademetan, an MDM2 Inhibitor, in Intimal Sarcoma with MDM2 Amplification: An Open-Label Phase Ib/II Study

Author

Koyama, Takafumi, primary, Shimizu, Toshio, primary, Kojima, Yuki, primary, Sudo, Kazuki, primary, Okuma, Hitomi Sumiyoshi, primary, Shimoi, Tatsunori, primary, Ichikawa, Hitoshi, primary, Kohsaka, Shinji, primary, Sadachi, Ryo, primary, Hirakawa, Akihiro, primary, Yoshida, Akihiko, primary, Ando, Reiko Makihara, primary, Ueno, Toshihide, primary, Yanagaki, Mitsuru, primary, Matsui, Naoko, primary, Nakamura, Kenichi, primary, Yamamoto, Noboru, primary, and Yonemori, Kan, primary

Published
2023
Full Text
View/download PDF

17. Supplementary Figure S4A from Clinical Activity and Exploratory Resistance Mechanism of Milademetan, an MDM2 Inhibitor, in Intimal Sarcoma with MDM2 Amplification: An Open-Label Phase Ib/II Study

Author

Koyama, Takafumi, primary, Shimizu, Toshio, primary, Kojima, Yuki, primary, Sudo, Kazuki, primary, Okuma, Hitomi Sumiyoshi, primary, Shimoi, Tatsunori, primary, Ichikawa, Hitoshi, primary, Kohsaka, Shinji, primary, Sadachi, Ryo, primary, Hirakawa, Akihiro, primary, Yoshida, Akihiko, primary, Ando, Reiko Makihara, primary, Ueno, Toshihide, primary, Yanagaki, Mitsuru, primary, Matsui, Naoko, primary, Nakamura, Kenichi, primary, Yamamoto, Noboru, primary, and Yonemori, Kan, primary

Published
2023
Full Text
View/download PDF

18. Supplementary Table S7 from Clinical Activity and Exploratory Resistance Mechanism of Milademetan, an MDM2 Inhibitor, in Intimal Sarcoma with MDM2 Amplification: An Open-Label Phase Ib/II Study

Author

Koyama, Takafumi, primary, Shimizu, Toshio, primary, Kojima, Yuki, primary, Sudo, Kazuki, primary, Okuma, Hitomi Sumiyoshi, primary, Shimoi, Tatsunori, primary, Ichikawa, Hitoshi, primary, Kohsaka, Shinji, primary, Sadachi, Ryo, primary, Hirakawa, Akihiro, primary, Yoshida, Akihiko, primary, Ando, Reiko Makihara, primary, Ueno, Toshihide, primary, Yanagaki, Mitsuru, primary, Matsui, Naoko, primary, Nakamura, Kenichi, primary, Yamamoto, Noboru, primary, and Yonemori, Kan, primary

Published
2023
Full Text
View/download PDF

19. Supplementary Table S4 from Clinical Activity and Exploratory Resistance Mechanism of Milademetan, an MDM2 Inhibitor, in Intimal Sarcoma with MDM2 Amplification: An Open-Label Phase Ib/II Study

Author

Koyama, Takafumi, primary, Shimizu, Toshio, primary, Kojima, Yuki, primary, Sudo, Kazuki, primary, Okuma, Hitomi Sumiyoshi, primary, Shimoi, Tatsunori, primary, Ichikawa, Hitoshi, primary, Kohsaka, Shinji, primary, Sadachi, Ryo, primary, Hirakawa, Akihiro, primary, Yoshida, Akihiko, primary, Ando, Reiko Makihara, primary, Ueno, Toshihide, primary, Yanagaki, Mitsuru, primary, Matsui, Naoko, primary, Nakamura, Kenichi, primary, Yamamoto, Noboru, primary, and Yonemori, Kan, primary

Published
2023
Full Text
View/download PDF

20. Supplementary Figure S2 from Clinical Activity and Exploratory Resistance Mechanism of Milademetan, an MDM2 Inhibitor, in Intimal Sarcoma with MDM2 Amplification: An Open-Label Phase Ib/II Study

Author

Koyama, Takafumi, primary, Shimizu, Toshio, primary, Kojima, Yuki, primary, Sudo, Kazuki, primary, Okuma, Hitomi Sumiyoshi, primary, Shimoi, Tatsunori, primary, Ichikawa, Hitoshi, primary, Kohsaka, Shinji, primary, Sadachi, Ryo, primary, Hirakawa, Akihiro, primary, Yoshida, Akihiko, primary, Ando, Reiko Makihara, primary, Ueno, Toshihide, primary, Yanagaki, Mitsuru, primary, Matsui, Naoko, primary, Nakamura, Kenichi, primary, Yamamoto, Noboru, primary, and Yonemori, Kan, primary

Published
2023
Full Text
View/download PDF

21. Supplementary Figure S6 from Clinical Activity and Exploratory Resistance Mechanism of Milademetan, an MDM2 Inhibitor, in Intimal Sarcoma with MDM2 Amplification: An Open-Label Phase Ib/II Study

Author

Koyama, Takafumi, primary, Shimizu, Toshio, primary, Kojima, Yuki, primary, Sudo, Kazuki, primary, Okuma, Hitomi Sumiyoshi, primary, Shimoi, Tatsunori, primary, Ichikawa, Hitoshi, primary, Kohsaka, Shinji, primary, Sadachi, Ryo, primary, Hirakawa, Akihiro, primary, Yoshida, Akihiko, primary, Ando, Reiko Makihara, primary, Ueno, Toshihide, primary, Yanagaki, Mitsuru, primary, Matsui, Naoko, primary, Nakamura, Kenichi, primary, Yamamoto, Noboru, primary, and Yonemori, Kan, primary

Published
2023
Full Text
View/download PDF

22. Data from Clinical Activity and Exploratory Resistance Mechanism of Milademetan, an MDM2 Inhibitor, in Intimal Sarcoma with MDM2 Amplification: An Open-Label Phase Ib/II Study

Author

Koyama, Takafumi, primary, Shimizu, Toshio, primary, Kojima, Yuki, primary, Sudo, Kazuki, primary, Okuma, Hitomi Sumiyoshi, primary, Shimoi, Tatsunori, primary, Ichikawa, Hitoshi, primary, Kohsaka, Shinji, primary, Sadachi, Ryo, primary, Hirakawa, Akihiro, primary, Yoshida, Akihiko, primary, Ando, Reiko Makihara, primary, Ueno, Toshihide, primary, Yanagaki, Mitsuru, primary, Matsui, Naoko, primary, Nakamura, Kenichi, primary, Yamamoto, Noboru, primary, and Yonemori, Kan, primary

Published
2023
Full Text
View/download PDF

23. Supplementary Figure S5 from Clinical Activity and Exploratory Resistance Mechanism of Milademetan, an MDM2 Inhibitor, in Intimal Sarcoma with MDM2 Amplification: An Open-Label Phase Ib/II Study

Author

Koyama, Takafumi, primary, Shimizu, Toshio, primary, Kojima, Yuki, primary, Sudo, Kazuki, primary, Okuma, Hitomi Sumiyoshi, primary, Shimoi, Tatsunori, primary, Ichikawa, Hitoshi, primary, Kohsaka, Shinji, primary, Sadachi, Ryo, primary, Hirakawa, Akihiro, primary, Yoshida, Akihiko, primary, Ando, Reiko Makihara, primary, Ueno, Toshihide, primary, Yanagaki, Mitsuru, primary, Matsui, Naoko, primary, Nakamura, Kenichi, primary, Yamamoto, Noboru, primary, and Yonemori, Kan, primary

Published
2023
Full Text
View/download PDF

24. Supplementary Table S5A from Clinical Activity and Exploratory Resistance Mechanism of Milademetan, an MDM2 Inhibitor, in Intimal Sarcoma with MDM2 Amplification: An Open-Label Phase Ib/II Study

Author

Koyama, Takafumi, primary, Shimizu, Toshio, primary, Kojima, Yuki, primary, Sudo, Kazuki, primary, Okuma, Hitomi Sumiyoshi, primary, Shimoi, Tatsunori, primary, Ichikawa, Hitoshi, primary, Kohsaka, Shinji, primary, Sadachi, Ryo, primary, Hirakawa, Akihiro, primary, Yoshida, Akihiko, primary, Ando, Reiko Makihara, primary, Ueno, Toshihide, primary, Yanagaki, Mitsuru, primary, Matsui, Naoko, primary, Nakamura, Kenichi, primary, Yamamoto, Noboru, primary, and Yonemori, Kan, primary

Published
2023
Full Text
View/download PDF

25. Supplementary Table S8 from Clinical Activity and Exploratory Resistance Mechanism of Milademetan, an MDM2 Inhibitor, in Intimal Sarcoma with MDM2 Amplification: An Open-Label Phase Ib/II Study

Author

Koyama, Takafumi, primary, Shimizu, Toshio, primary, Kojima, Yuki, primary, Sudo, Kazuki, primary, Okuma, Hitomi Sumiyoshi, primary, Shimoi, Tatsunori, primary, Ichikawa, Hitoshi, primary, Kohsaka, Shinji, primary, Sadachi, Ryo, primary, Hirakawa, Akihiro, primary, Yoshida, Akihiko, primary, Ando, Reiko Makihara, primary, Ueno, Toshihide, primary, Yanagaki, Mitsuru, primary, Matsui, Naoko, primary, Nakamura, Kenichi, primary, Yamamoto, Noboru, primary, and Yonemori, Kan, primary

Published
2023
Full Text
View/download PDF

26. Supplementary Figure S3 from Clinical Activity and Exploratory Resistance Mechanism of Milademetan, an MDM2 Inhibitor, in Intimal Sarcoma with MDM2 Amplification: An Open-Label Phase Ib/II Study

Author

Koyama, Takafumi, primary, Shimizu, Toshio, primary, Kojima, Yuki, primary, Sudo, Kazuki, primary, Okuma, Hitomi Sumiyoshi, primary, Shimoi, Tatsunori, primary, Ichikawa, Hitoshi, primary, Kohsaka, Shinji, primary, Sadachi, Ryo, primary, Hirakawa, Akihiro, primary, Yoshida, Akihiko, primary, Ando, Reiko Makihara, primary, Ueno, Toshihide, primary, Yanagaki, Mitsuru, primary, Matsui, Naoko, primary, Nakamura, Kenichi, primary, Yamamoto, Noboru, primary, and Yonemori, Kan, primary

Published
2023
Full Text
View/download PDF

27. Supplementary Figure S5 from Clinical Activity and Exploratory Resistance Mechanism of Milademetan, an MDM2 Inhibitor, in Intimal Sarcoma with MDM2 Amplification: An Open-Label Phase Ib/II Study

Author

Koyama, Takafumi, primary, Shimizu, Toshio, primary, Kojima, Yuki, primary, Sudo, Kazuki, primary, Okuma, Hitomi Sumiyoshi, primary, Shimoi, Tatsunori, primary, Ichikawa, Hitoshi, primary, Kohsaka, Shinji, primary, Sadachi, Ryo, primary, Hirakawa, Akihiro, primary, Yoshida, Akihiko, primary, Ando, Reiko Makihara, primary, Ueno, Toshihide, primary, Yanagaki, Mitsuru, primary, Matsui, Naoko, primary, Nakamura, Kenichi, primary, Yamamoto, Noboru, primary, and Yonemori, Kan, primary

Published
2023
Full Text
View/download PDF

28. Supplementary Table S1 from Clinical Activity and Exploratory Resistance Mechanism of Milademetan, an MDM2 Inhibitor, in Intimal Sarcoma with MDM2 Amplification: An Open-Label Phase Ib/II Study

Author

Koyama, Takafumi, primary, Shimizu, Toshio, primary, Kojima, Yuki, primary, Sudo, Kazuki, primary, Okuma, Hitomi Sumiyoshi, primary, Shimoi, Tatsunori, primary, Ichikawa, Hitoshi, primary, Kohsaka, Shinji, primary, Sadachi, Ryo, primary, Hirakawa, Akihiro, primary, Yoshida, Akihiko, primary, Ando, Reiko Makihara, primary, Ueno, Toshihide, primary, Yanagaki, Mitsuru, primary, Matsui, Naoko, primary, Nakamura, Kenichi, primary, Yamamoto, Noboru, primary, and Yonemori, Kan, primary

Published
2023
Full Text
View/download PDF

29. Supplementary Table S5A from Clinical Activity and Exploratory Resistance Mechanism of Milademetan, an MDM2 Inhibitor, in Intimal Sarcoma with MDM2 Amplification: An Open-Label Phase Ib/II Study

Author

Koyama, Takafumi, primary, Shimizu, Toshio, primary, Kojima, Yuki, primary, Sudo, Kazuki, primary, Okuma, Hitomi Sumiyoshi, primary, Shimoi, Tatsunori, primary, Ichikawa, Hitoshi, primary, Kohsaka, Shinji, primary, Sadachi, Ryo, primary, Hirakawa, Akihiro, primary, Yoshida, Akihiko, primary, Ando, Reiko Makihara, primary, Ueno, Toshihide, primary, Yanagaki, Mitsuru, primary, Matsui, Naoko, primary, Nakamura, Kenichi, primary, Yamamoto, Noboru, primary, and Yonemori, Kan, primary

Published
2023
Full Text
View/download PDF

30. Supplementary Table S6 from Clinical Activity and Exploratory Resistance Mechanism of Milademetan, an MDM2 Inhibitor, in Intimal Sarcoma with MDM2 Amplification: An Open-Label Phase Ib/II Study

Author

Koyama, Takafumi, primary, Shimizu, Toshio, primary, Kojima, Yuki, primary, Sudo, Kazuki, primary, Okuma, Hitomi Sumiyoshi, primary, Shimoi, Tatsunori, primary, Ichikawa, Hitoshi, primary, Kohsaka, Shinji, primary, Sadachi, Ryo, primary, Hirakawa, Akihiro, primary, Yoshida, Akihiko, primary, Ando, Reiko Makihara, primary, Ueno, Toshihide, primary, Yanagaki, Mitsuru, primary, Matsui, Naoko, primary, Nakamura, Kenichi, primary, Yamamoto, Noboru, primary, and Yonemori, Kan, primary

Published
2023
Full Text
View/download PDF

31. Supplementary Table S6 from Clinical Activity and Exploratory Resistance Mechanism of Milademetan, an MDM2 Inhibitor, in Intimal Sarcoma with MDM2 Amplification: An Open-Label Phase Ib/II Study

Author

Koyama, Takafumi, primary, Shimizu, Toshio, primary, Kojima, Yuki, primary, Sudo, Kazuki, primary, Okuma, Hitomi Sumiyoshi, primary, Shimoi, Tatsunori, primary, Ichikawa, Hitoshi, primary, Kohsaka, Shinji, primary, Sadachi, Ryo, primary, Hirakawa, Akihiro, primary, Yoshida, Akihiko, primary, Ando, Reiko Makihara, primary, Ueno, Toshihide, primary, Yanagaki, Mitsuru, primary, Matsui, Naoko, primary, Nakamura, Kenichi, primary, Yamamoto, Noboru, primary, and Yonemori, Kan, primary

Published
2023
Full Text
View/download PDF

32. Supplementary Figure S3 from Clinical Activity and Exploratory Resistance Mechanism of Milademetan, an MDM2 Inhibitor, in Intimal Sarcoma with MDM2 Amplification: An Open-Label Phase Ib/II Study

Author

Koyama, Takafumi, primary, Shimizu, Toshio, primary, Kojima, Yuki, primary, Sudo, Kazuki, primary, Okuma, Hitomi Sumiyoshi, primary, Shimoi, Tatsunori, primary, Ichikawa, Hitoshi, primary, Kohsaka, Shinji, primary, Sadachi, Ryo, primary, Hirakawa, Akihiro, primary, Yoshida, Akihiko, primary, Ando, Reiko Makihara, primary, Ueno, Toshihide, primary, Yanagaki, Mitsuru, primary, Matsui, Naoko, primary, Nakamura, Kenichi, primary, Yamamoto, Noboru, primary, and Yonemori, Kan, primary

Published
2023
Full Text
View/download PDF

33. Supplementary Figure S1 from Clinical Activity and Exploratory Resistance Mechanism of Milademetan, an MDM2 Inhibitor, in Intimal Sarcoma with MDM2 Amplification: An Open-Label Phase Ib/II Study

Author

Koyama, Takafumi, primary, Shimizu, Toshio, primary, Kojima, Yuki, primary, Sudo, Kazuki, primary, Okuma, Hitomi Sumiyoshi, primary, Shimoi, Tatsunori, primary, Ichikawa, Hitoshi, primary, Kohsaka, Shinji, primary, Sadachi, Ryo, primary, Hirakawa, Akihiro, primary, Yoshida, Akihiko, primary, Ando, Reiko Makihara, primary, Ueno, Toshihide, primary, Yanagaki, Mitsuru, primary, Matsui, Naoko, primary, Nakamura, Kenichi, primary, Yamamoto, Noboru, primary, and Yonemori, Kan, primary

Published
2023
Full Text
View/download PDF

34. Supplementary Table S3A-B from Clinical Activity and Exploratory Resistance Mechanism of Milademetan, an MDM2 Inhibitor, in Intimal Sarcoma with MDM2 Amplification: An Open-Label Phase Ib/II Study

Author

Koyama, Takafumi, primary, Shimizu, Toshio, primary, Kojima, Yuki, primary, Sudo, Kazuki, primary, Okuma, Hitomi Sumiyoshi, primary, Shimoi, Tatsunori, primary, Ichikawa, Hitoshi, primary, Kohsaka, Shinji, primary, Sadachi, Ryo, primary, Hirakawa, Akihiro, primary, Yoshida, Akihiko, primary, Ando, Reiko Makihara, primary, Ueno, Toshihide, primary, Yanagaki, Mitsuru, primary, Matsui, Naoko, primary, Nakamura, Kenichi, primary, Yamamoto, Noboru, primary, and Yonemori, Kan, primary

Published
2023
Full Text
View/download PDF

35. Supplementary Figure S2 from Clinical Activity and Exploratory Resistance Mechanism of Milademetan, an MDM2 Inhibitor, in Intimal Sarcoma with MDM2 Amplification: An Open-Label Phase Ib/II Study

Author

Koyama, Takafumi, primary, Shimizu, Toshio, primary, Kojima, Yuki, primary, Sudo, Kazuki, primary, Okuma, Hitomi Sumiyoshi, primary, Shimoi, Tatsunori, primary, Ichikawa, Hitoshi, primary, Kohsaka, Shinji, primary, Sadachi, Ryo, primary, Hirakawa, Akihiro, primary, Yoshida, Akihiko, primary, Ando, Reiko Makihara, primary, Ueno, Toshihide, primary, Yanagaki, Mitsuru, primary, Matsui, Naoko, primary, Nakamura, Kenichi, primary, Yamamoto, Noboru, primary, and Yonemori, Kan, primary

Published
2023
Full Text
View/download PDF

36. Supplementary Figure S1 from Clinical Activity and Exploratory Resistance Mechanism of Milademetan, an MDM2 Inhibitor, in Intimal Sarcoma with MDM2 Amplification: An Open-Label Phase Ib/II Study

Author

Koyama, Takafumi, primary, Shimizu, Toshio, primary, Kojima, Yuki, primary, Sudo, Kazuki, primary, Okuma, Hitomi Sumiyoshi, primary, Shimoi, Tatsunori, primary, Ichikawa, Hitoshi, primary, Kohsaka, Shinji, primary, Sadachi, Ryo, primary, Hirakawa, Akihiro, primary, Yoshida, Akihiko, primary, Ando, Reiko Makihara, primary, Ueno, Toshihide, primary, Yanagaki, Mitsuru, primary, Matsui, Naoko, primary, Nakamura, Kenichi, primary, Yamamoto, Noboru, primary, and Yonemori, Kan, primary

Published
2023
Full Text
View/download PDF

37. Supplementary Figure S4A from Clinical Activity and Exploratory Resistance Mechanism of Milademetan, an MDM2 Inhibitor, in Intimal Sarcoma with MDM2 Amplification: An Open-Label Phase Ib/II Study

Author

Koyama, Takafumi, primary, Shimizu, Toshio, primary, Kojima, Yuki, primary, Sudo, Kazuki, primary, Okuma, Hitomi Sumiyoshi, primary, Shimoi, Tatsunori, primary, Ichikawa, Hitoshi, primary, Kohsaka, Shinji, primary, Sadachi, Ryo, primary, Hirakawa, Akihiro, primary, Yoshida, Akihiko, primary, Ando, Reiko Makihara, primary, Ueno, Toshihide, primary, Yanagaki, Mitsuru, primary, Matsui, Naoko, primary, Nakamura, Kenichi, primary, Yamamoto, Noboru, primary, and Yonemori, Kan, primary

Published
2023
Full Text
View/download PDF

38. Supplementary Figure S5 from Clinical Activity and Exploratory Resistance Mechanism of Milademetan, an MDM2 Inhibitor, in Intimal Sarcoma with MDM2 Amplification: An Open-Label Phase Ib/II Study

Author

Koyama, Takafumi, primary, Shimizu, Toshio, primary, Kojima, Yuki, primary, Sudo, Kazuki, primary, Okuma, Hitomi Sumiyoshi, primary, Shimoi, Tatsunori, primary, Ichikawa, Hitoshi, primary, Kohsaka, Shinji, primary, Sadachi, Ryo, primary, Hirakawa, Akihiro, primary, Yoshida, Akihiko, primary, Ando, Reiko Makihara, primary, Ueno, Toshihide, primary, Yanagaki, Mitsuru, primary, Matsui, Naoko, primary, Nakamura, Kenichi, primary, Yamamoto, Noboru, primary, and Yonemori, Kan, primary

Published
2023
Full Text
View/download PDF

39. Clinical Activity and Exploratory Resistance Mechanism of Milademetan, an MDM2 Inhibitor, in Intimal Sarcoma with MDM2 Amplification: An Open-Label Phase Ib/II Study

Author

Koyama, Takafumi, primary, Shimizu, Toshio, additional, Kojima, Yuki, additional, Sudo, Kazuki, additional, Okuma, Hitomi Sumiyoshi, additional, Shimoi, Tatsunori, additional, Ichikawa, Hitoshi, additional, Kohsaka, Shinji, additional, Sadachi, Ryo, additional, Hirakawa, Akihiro, additional, Yoshida, Akihiko, additional, Ando, Reiko Makihara, additional, Ueno, Toshihide, additional, Yanagaki, Mitsuru, additional, Matsui, Naoko, additional, Nakamura, Kenichi, additional, Yamamoto, Noboru, additional, and Yonemori, Kan, additional

Published
2023
Full Text
View/download PDF

40. Supplementary Figure 2 from Phase 1b/2 Study of a Liposomal Formulation of Eribulin (E7389-LF) Plus Nivolumab in Patients with Advanced Solid Tumors: Results from Phase 1b

Author

Ida, Hanae, primary, Shimizu, Toshio, primary, Nishino, Makoto, primary, Nakamura, Yoshiaki, primary, Yazaki, Shu, primary, Katsuya, Yuki, primary, Sato, Jun, primary, Koyama, Takafumi, primary, Iwasa, Satoru, primary, Sudo, Kazuki, primary, Kondo, Shunsuke, primary, Yonemori, Kan, primary, Shitara, Kohei, primary, Shiono, Satoshi, primary, Matsuoka, Daiko, primary, Yasuda, Keisuke, primary, Otake, Yohei, primary, Suzuki, Takuya, primary, Takase, Takao, primary, Takashima, Shuya, primary, Yamaguchi, Kohei, primary, Semba, Taro, primary, and Yamamoto, Noboru, primary

Published
2023
Full Text
View/download PDF

41. Supplementary Table 5 from Phase 1b/2 Study of a Liposomal Formulation of Eribulin (E7389-LF) Plus Nivolumab in Patients with Advanced Solid Tumors: Results from Phase 1b

Author

Ida, Hanae, primary, Shimizu, Toshio, primary, Nishino, Makoto, primary, Nakamura, Yoshiaki, primary, Yazaki, Shu, primary, Katsuya, Yuki, primary, Sato, Jun, primary, Koyama, Takafumi, primary, Iwasa, Satoru, primary, Sudo, Kazuki, primary, Kondo, Shunsuke, primary, Yonemori, Kan, primary, Shitara, Kohei, primary, Shiono, Satoshi, primary, Matsuoka, Daiko, primary, Yasuda, Keisuke, primary, Otake, Yohei, primary, Suzuki, Takuya, primary, Takase, Takao, primary, Takashima, Shuya, primary, Yamaguchi, Kohei, primary, Semba, Taro, primary, and Yamamoto, Noboru, primary

Published
2023
Full Text
View/download PDF

42. Supplementary Figure 4 from Phase 1b/2 Study of a Liposomal Formulation of Eribulin (E7389-LF) Plus Nivolumab in Patients with Advanced Solid Tumors: Results from Phase 1b

Author

Ida, Hanae, primary, Shimizu, Toshio, primary, Nishino, Makoto, primary, Nakamura, Yoshiaki, primary, Yazaki, Shu, primary, Katsuya, Yuki, primary, Sato, Jun, primary, Koyama, Takafumi, primary, Iwasa, Satoru, primary, Sudo, Kazuki, primary, Kondo, Shunsuke, primary, Yonemori, Kan, primary, Shitara, Kohei, primary, Shiono, Satoshi, primary, Matsuoka, Daiko, primary, Yasuda, Keisuke, primary, Otake, Yohei, primary, Suzuki, Takuya, primary, Takase, Takao, primary, Takashima, Shuya, primary, Yamaguchi, Kohei, primary, Semba, Taro, primary, and Yamamoto, Noboru, primary

Published
2023
Full Text
View/download PDF

43. Supplementary Table 3 from Phase 1b/2 Study of a Liposomal Formulation of Eribulin (E7389-LF) Plus Nivolumab in Patients with Advanced Solid Tumors: Results from Phase 1b

Author

Ida, Hanae, primary, Shimizu, Toshio, primary, Nishino, Makoto, primary, Nakamura, Yoshiaki, primary, Yazaki, Shu, primary, Katsuya, Yuki, primary, Sato, Jun, primary, Koyama, Takafumi, primary, Iwasa, Satoru, primary, Sudo, Kazuki, primary, Kondo, Shunsuke, primary, Yonemori, Kan, primary, Shitara, Kohei, primary, Shiono, Satoshi, primary, Matsuoka, Daiko, primary, Yasuda, Keisuke, primary, Otake, Yohei, primary, Suzuki, Takuya, primary, Takase, Takao, primary, Takashima, Shuya, primary, Yamaguchi, Kohei, primary, Semba, Taro, primary, and Yamamoto, Noboru, primary

Published
2023
Full Text
View/download PDF

44. Supplementary Table 4 from Phase 1b/2 Study of a Liposomal Formulation of Eribulin (E7389-LF) Plus Nivolumab in Patients with Advanced Solid Tumors: Results from Phase 1b

Author

Ida, Hanae, primary, Shimizu, Toshio, primary, Nishino, Makoto, primary, Nakamura, Yoshiaki, primary, Yazaki, Shu, primary, Katsuya, Yuki, primary, Sato, Jun, primary, Koyama, Takafumi, primary, Iwasa, Satoru, primary, Sudo, Kazuki, primary, Kondo, Shunsuke, primary, Yonemori, Kan, primary, Shitara, Kohei, primary, Shiono, Satoshi, primary, Matsuoka, Daiko, primary, Yasuda, Keisuke, primary, Otake, Yohei, primary, Suzuki, Takuya, primary, Takase, Takao, primary, Takashima, Shuya, primary, Yamaguchi, Kohei, primary, Semba, Taro, primary, and Yamamoto, Noboru, primary

Published
2023
Full Text
View/download PDF

45. Supplementary Table 2 from Phase 1b/2 Study of a Liposomal Formulation of Eribulin (E7389-LF) Plus Nivolumab in Patients with Advanced Solid Tumors: Results from Phase 1b

Author

Ida, Hanae, primary, Shimizu, Toshio, primary, Nishino, Makoto, primary, Nakamura, Yoshiaki, primary, Yazaki, Shu, primary, Katsuya, Yuki, primary, Sato, Jun, primary, Koyama, Takafumi, primary, Iwasa, Satoru, primary, Sudo, Kazuki, primary, Kondo, Shunsuke, primary, Yonemori, Kan, primary, Shitara, Kohei, primary, Shiono, Satoshi, primary, Matsuoka, Daiko, primary, Yasuda, Keisuke, primary, Otake, Yohei, primary, Suzuki, Takuya, primary, Takase, Takao, primary, Takashima, Shuya, primary, Yamaguchi, Kohei, primary, Semba, Taro, primary, and Yamamoto, Noboru, primary

Published
2023
Full Text
View/download PDF

46. Supplementary Table 4 from Phase 1b/2 Study of a Liposomal Formulation of Eribulin (E7389-LF) Plus Nivolumab in Patients with Advanced Solid Tumors: Results from Phase 1b

Author

Ida, Hanae, primary, Shimizu, Toshio, primary, Nishino, Makoto, primary, Nakamura, Yoshiaki, primary, Yazaki, Shu, primary, Katsuya, Yuki, primary, Sato, Jun, primary, Koyama, Takafumi, primary, Iwasa, Satoru, primary, Sudo, Kazuki, primary, Kondo, Shunsuke, primary, Yonemori, Kan, primary, Shitara, Kohei, primary, Shiono, Satoshi, primary, Matsuoka, Daiko, primary, Yasuda, Keisuke, primary, Otake, Yohei, primary, Suzuki, Takuya, primary, Takase, Takao, primary, Takashima, Shuya, primary, Yamaguchi, Kohei, primary, Semba, Taro, primary, and Yamamoto, Noboru, primary

Published
2023
Full Text
View/download PDF

47. Supplementary Table 3 from Phase 1b/2 Study of a Liposomal Formulation of Eribulin (E7389-LF) Plus Nivolumab in Patients with Advanced Solid Tumors: Results from Phase 1b

Author

Ida, Hanae, primary, Shimizu, Toshio, primary, Nishino, Makoto, primary, Nakamura, Yoshiaki, primary, Yazaki, Shu, primary, Katsuya, Yuki, primary, Sato, Jun, primary, Koyama, Takafumi, primary, Iwasa, Satoru, primary, Sudo, Kazuki, primary, Kondo, Shunsuke, primary, Yonemori, Kan, primary, Shitara, Kohei, primary, Shiono, Satoshi, primary, Matsuoka, Daiko, primary, Yasuda, Keisuke, primary, Otake, Yohei, primary, Suzuki, Takuya, primary, Takase, Takao, primary, Takashima, Shuya, primary, Yamaguchi, Kohei, primary, Semba, Taro, primary, and Yamamoto, Noboru, primary

Published
2023
Full Text
View/download PDF

48. Supplementary Figure 3 from Phase 1b/2 Study of a Liposomal Formulation of Eribulin (E7389-LF) Plus Nivolumab in Patients with Advanced Solid Tumors: Results from Phase 1b

Author

Ida, Hanae, primary, Shimizu, Toshio, primary, Nishino, Makoto, primary, Nakamura, Yoshiaki, primary, Yazaki, Shu, primary, Katsuya, Yuki, primary, Sato, Jun, primary, Koyama, Takafumi, primary, Iwasa, Satoru, primary, Sudo, Kazuki, primary, Kondo, Shunsuke, primary, Yonemori, Kan, primary, Shitara, Kohei, primary, Shiono, Satoshi, primary, Matsuoka, Daiko, primary, Yasuda, Keisuke, primary, Otake, Yohei, primary, Suzuki, Takuya, primary, Takase, Takao, primary, Takashima, Shuya, primary, Yamaguchi, Kohei, primary, Semba, Taro, primary, and Yamamoto, Noboru, primary

Published
2023
Full Text
View/download PDF

49. Supplementary Table 1 from Phase 1b/2 Study of a Liposomal Formulation of Eribulin (E7389-LF) Plus Nivolumab in Patients with Advanced Solid Tumors: Results from Phase 1b

Author

Ida, Hanae, primary, Shimizu, Toshio, primary, Nishino, Makoto, primary, Nakamura, Yoshiaki, primary, Yazaki, Shu, primary, Katsuya, Yuki, primary, Sato, Jun, primary, Koyama, Takafumi, primary, Iwasa, Satoru, primary, Sudo, Kazuki, primary, Kondo, Shunsuke, primary, Yonemori, Kan, primary, Shitara, Kohei, primary, Shiono, Satoshi, primary, Matsuoka, Daiko, primary, Yasuda, Keisuke, primary, Otake, Yohei, primary, Suzuki, Takuya, primary, Takase, Takao, primary, Takashima, Shuya, primary, Yamaguchi, Kohei, primary, Semba, Taro, primary, and Yamamoto, Noboru, primary

Published
2023
Full Text
View/download PDF

50. Supplementary Table 2 from Phase 1b/2 Study of a Liposomal Formulation of Eribulin (E7389-LF) Plus Nivolumab in Patients with Advanced Solid Tumors: Results from Phase 1b

Author

Ida, Hanae, primary, Shimizu, Toshio, primary, Nishino, Makoto, primary, Nakamura, Yoshiaki, primary, Yazaki, Shu, primary, Katsuya, Yuki, primary, Sato, Jun, primary, Koyama, Takafumi, primary, Iwasa, Satoru, primary, Sudo, Kazuki, primary, Kondo, Shunsuke, primary, Yonemori, Kan, primary, Shitara, Kohei, primary, Shiono, Satoshi, primary, Matsuoka, Daiko, primary, Yasuda, Keisuke, primary, Otake, Yohei, primary, Suzuki, Takuya, primary, Takase, Takao, primary, Takashima, Shuya, primary, Yamaguchi, Kohei, primary, Semba, Taro, primary, and Yamamoto, Noboru, primary

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results